Cellebrite price target lowered to $20 from $22 at JPMorgan

JPMorgan lowered the firm’s price target on Cellebrite (CLBT) to $20 from $22 and keeps an Overweight rating on the shares as part of a security software earnings preview. Demand remained relatively healthy for high priority budget categories, with identity and data security increasing in priority, the analyst tells investors in a research note. The firm established 2026 based price targets across its coverage for those that have not yet been updated.